Kornimate/medical-research-clean huggingface dataset:
assessing free immunoglobulin light chains in patients with myeloma

Conditions: Multiple Myeloma

Summary: multiple myeloma is a disorder in which malignant plasma cells accumulate in the bone marrow. these plasma cells produce an abnormal protein called paraprotein / m spike in the serum which can be serially monitored to assess the response of tumour on therapy. the paraprotein has a heavy chain which can be either igg, iga, igm or igd and a light chain which can be either kappa or lambda. at present, these can be assessed by serum and urine electrophoresis (spe and upe). these techniques are relatively insensitive and poorly quantitative compared with other immunoassays for tumour markers. the potential of serum free light chain (flc) measurement as a marker for myeloma has been recognised for some time. however, development of such assays has proved elusive, primarily due to the difficulty in developing assays that are both convenient to use and have the required specificity to measure flc in serum. recently , the assay has been standardised and is in use. its likely that the assessment of flc might be a sensitive marker of documenting complete remission in patients with myeloma. the aim of this study is to study the flc in patients with myeloma in complete remission (cr) to see if patients have cr documented by standard criteria- are the free light chains still positive and if so are they better markers of remission. the samples will be collected and tested in batches of 60 each.


Eligibility criteria:
inclusion criteria: * multiple myeloma patients in cr exclusion criteria: * not being able to give consent
oto-413 in subjects with speech-in-noise hearing impairment

Conditions: Sensorineural Hearing Loss

Summary: the purpose of this study is to evaluate the safety, tolerability, and exploratory efficacy of oto-413 administered as an intratympanic injection for the treatment of speech-in-noise hearing impairment.


Eligibility criteria:
inclusion criteria: * subject has audiometrically-defined normal hearing or up to moderately severe hearing impairment. * subject has self-reported difficulty hearing in noisy environments for at least 6 months prior to screening. * subject exhibited a speech-in-noise hearing deficit in at least one ear. exclusion criteria: * subject is pregnant or lactating. * subject has the following hearing disorders or any other hearing disorders that may impact the efficacy assessments or safety of the subject in the opinion of the investigator: meniere's disease, congenital hearing loss, or genetic sensorineural hearing loss. * subject has a cochlear implant or consistently uses a hearing aid. * subject has worked at least 5 years as a professional musician or has had at least 15 years of formal musical training. * subject self-reports bothersome, subjective tinnitus and is consistently aware of their tinnitus throughout much of the waking day.

Keywords: hearing loss speech-in-noise synaptopathy hearing impairment hidden hearing loss
markers of alzheimers disease after propofol or isoflurane anesthesia

Conditions: General Anesthesia

Summary: previous work in animal models suggests that inhalational anesthetic agents may accelerate alzheimer's disease pathogenesis, but it is unclear to what extent this may happen in humans. here, the investigators propose to measure alzheimer's disease-related neural markers in the cerebrospinal fluid (csf) of patients exposed to anesthesia while undergoing neurosurgical procedures that require lumbar drain placement. patients will be randomized to either receive inhalation anesthesia with isoflurane or intravenous anesthesia with propofol. csf and blood samples will each be collected at the induction of anesthesia, and then again ten and twenty-four hours later. csf samples will be assayed for amyloid beta, tau, and other alzheimer's disease-associated markers; blood samples will be assayed for serum inflammatory markers and used for genotyping studies. these studies should clarify the effect of common anesthetic agents on alzheimer's disease related neural markers.


Eligibility criteria:
inclusion criteria: * age 18 and above * seen in neurosurgical clinic, and scheduled for operative aneurysm repair or other neurosurgical procedure necessitating lumbar drain placement. * ability to speak english. * ability to understand consent forms, and to give informed consent. exclusion criteria: * age less than 18 * lumbar drain is not placed * not eligible for one of the anesthetics (inhaled isoflurane or iv propofol) * inmate of a correctional facility (i.e. prisoners). * pregnancy. pregnancy is ruled out as standard of care before cranial surgery, based on clinical history and/or hcg testing

Keywords: general anesthesia alzheimers disease cognitive decline
bivalirudin with prolonged full dose infusion versus heparin alone during emergency pci

Conditions: ST Elevation Myocardial Infarction

Summary: this study is aimed to investigate if the bivaliruding with prolonged full dose infusion after pci is superior to heparin alone in reducing 30-day mortality or major bleeding for patients with stemi treated with emergency pci. a total of 6000 stemi patients will be enrolled and randomly assigned to receive bivalirudin or heparin during emergency pci in a 1:1 ratio. this study will provide key evidence for peri-operative anticoagulant therapy decisions in stemi patients.


Eligibility criteria:
inclusion criteria: * any age; * stemi patients undergoing primary pci with st elevation≥1mm in≥2 contiguous leads or new lbbb with symptom onset 48h; * patients requiring staged revascularization of non-culprit vessels within 30 days may be enrolled. in such cases the same antithrombotic agents and pci procedures must be used in the staged procedure consistent with the index procedure pci, in particular the assigned antithrombin agent heparin vs. bivalirudin); * dual antiplatelet drugs must be administrated according to guidelines before pci (loading doses and maintenance doses of aspirin and clopidogrel or ticagrelor); * the subject or legal representative has been informed of the nature of the study, understood the provisions of the protocol, was able to ensure adherence, and signed informed consent. exclusion criteria: * not suitable for emergency primary pci; * stemi treated by thrombolysis; * patients received heparin, lmwh, fondaparinux, bivalirudin, or gpi within 48 hours before the index pci; * mechanical complications (such as ventricular septal rupture, papillary muscle rupture with acute mitral regurgitation, etc.); * known allergy or contraindications to heparin, bivalirudin, aspirin, or both clopidogrel and ticagrelor * patients in whom the investigators consider inappropriate to participate in this study (eg, have participated in another drug/instrument study or undergoing another drug/instrument study).

Keywords: primary percutaneous coronary intervention anticoagulant agents bivalirudin heparin
efficacy of manual therapy in migraine

Conditions: MIGRAINE

Summary: objective: the aim of this study was to determine the efficacy of suboccipital inhibitory manual therapy treatment in migraine compared to treatment based on myofascial trigger points (mtrps) and their stretching, often being hypersensitive in patients with migraine. material and methods: 27 patients in two groups participated in the study: a) the control group received combined techniques based on mtrps and bilateral stretching in the trapezius and sternocleidomastoid muscle (scm); b) the experimental group was applied the same techniques as those applied in the control group plus suboccipital inhibition. the treatment lasted for 8 weeks and the impact, disability and quality of life were assessed in both groups.

introduction migraine is a highly prevalent disorder entailing substantial costs. manual therapy offers an attractive option as an alternative to medical treatment or used in combination therewith. treatment focused on the soft tissues of the suboccitpital region has been studied in other types of headaches but not in migraine. objective: the aim of this study was to determine the efficacy of suboccipital inhibitory manual therapy treatment in migraine compared to treatment based on myofascial trigger points (mtrps) and their stretching, often being hypersensitive in patients with migraine. material and methods: 27 patients in two groups participated in the study: a) the control group received combined techniques based on mtrps and bilateral stretching in the trapezius and sternocleidomastoid muscle (scm); b) the experimental group was applied the same techniques as those applied in the control group plus suboccipital inhibition. the treatment lasted for 8 weeks and the impact, disability and quality of life were assessed in both groups.

Eligibility criteria:
inclusion criteria: * patients were diagnosed according to the criteria established by the ihs exclusion criteria: * patients were excluded if they presented with other headache types, if their headache was triggered by neck movement, or if they presented with dizziness, hypertension, emotional stress, psychological disorders, cardiovascular disease or pregnancy.

Keywords: efficacy, manual therapy, migraine, quality of life
lidocaine patches for attenuating the pain of venipuncture intravenous cannulation

Conditions: We Focus on the Pain of Venipuncture and Intravenous Cannulation

Summary: venipuncture and intravenous cannulation are the most common painful procedures, especially for the penitents who must receive large diameter venous catheter before surgery. in present study we would evaluate the safety and validity of lidocaine patches releasing such pain.


Eligibility criteria:
inclusion criteria: * patients who want to participate present study and sign the informed consent form * age from 18 to 65 years old * patients who need intravenous cannulation before surgery * asa class i-ii and selected patients exclusion criteria: * allergic to lidocaine or any other amide local anesthetics or any other medicine * allergic skin(allergic to past agent or other topical used medicine) * skin injured or inflection exist in the local site to patch * sensation disturbed in any limb * severe liver and kidney original disease:blood aspertate aminotransferase and alanine transaminase increased 1.5 times more than normal concentration; blood creatinine is higher than the normal range. * hemoglobin \<80g/l * ecg is significantly abnormal * pregnant or possible pregnant or breastfeeding woman * patient who has consciousness disturbance can not make credible dialog with investigator. * those who are using other medicine may affect the evaluation of present patch * those who have participated in other clinical trail in the past three months * those excluded by investigator believed other reasons.

Keywords: lidocaine patches pain intravenous cannulation
multi-omics research of idopathic normal pressure hydrocephalus (inph)

Conditions: Idiopathic Normal Pressure Hydrocephalus

Summary: the research is designed to study the prognostic factors of ventriculoperitoneal (vp) shunt for inph by multi-omics research

preoperative t1-mri, functional mri and diffusion mri imaging data of inph patients were collected. the clinical assessment was performed before/after the lumbar puncture test and 6 months after vp shunt. clinical assessment included mini-mental state examination (mmse), gait scores, kiefer score, and modified rankin scale (mrs). the cerebrospinal fluid was collected by tap-test, and 6 months after surgery by puncturing in the vp device pump. methods- the primary methods used are: 1. the cerebrospinal fluid proteomic analysis of inph patients before and after vp shunt surgery. 2. the structral and functional mri analysis of inph patients 3. the clinical assessment of mmse, gait scores, kiefer score, and mrs. objective- to study the prognostic factors of vp shunt for inph.

Eligibility criteria:
inclusion criteria: * age ≥ 60 years; * diagnosis of inph based on clinical assessment * participant is able to give written informed consent exclusion criteria: * combining ad and parkinson's disease and other nervous system diseases * participant is not medically available for shunt surgery * secondary nph

Keywords: idiopathic normal pressure hydrocephalus prognostic factor ventriculoperitoneal shunt cerebrospinal fluid proteomics
comparison of the user experience of four nasal aspirators in infants

Conditions: Upper Respiratory Tract Infection

Summary: the goal of this clinical trial is to compare the caregiver's user experience, and overall impacts on an infant's cold symptoms between four nasal aspirator devices. these devices are normally used to relieve congestion in infants. when they are sick by softening and suctioning mucus from the nose. the main questions it aims to answer are: what is the caregiver's user experience of the nozebot electric nasal aspirator compared to three commonly accessible nasal aspirator devices? are there changes in the infant's sleeping, feeding, or breathing as reported by the caregiver when using the nozebot compared to the three other nasal aspirator devices? are there changes in their caregiver's habits when using the nozebot compared to the three other nasal aspirator devices? researchers will compare the self-reported measures of caregiver's user experience, reported changes to their infant's symptoms, and reported changes to their own sleeping and care habits between the nozebot electric nasal aspirator and three comparator devices: the nosefrida snotsucker, the hydrasense baby nasal aspirator kit, and the braun electric nasal aspirator. participants will be assigned to receive one of the four devices at the start of their participation. they will be asked to use the assigned device at home according to the device instructions during two periods: (1) for 10 days while their infant is sick, and (2) for up to 3 months after. during these periods, participants will be asked to complete online surveys at predetermined intervals to report the user experience, any changes to their infant's sleeping, feeding or breathing, and any changes to their own sleeping habits and perceived stress levels. these intervals for survey completion are: (i) after 1-2 days of use while their infant is sick, (ii) after 4-5 days of use while their infant is sick, (iii) after 7-10 days of use while their infant is sick, and then (iv) biweekly for 3 months.


Eligibility criteria:
inclusion criteria a parent(s)/caregiver(s)/family will be eligible to participate if: * they have a child between 2 months - 18 months of age * they are seeking outpatient care for that child for a respiratory illness (cold, flu, rsv) at the kids come first care clinic * the child does not have any contraindications to the use of a nasal aspirator * the parent(s)/caregiver(s) are fluent in english exclusion criteria a parent(s)/caregiver(s)/family will be ineligible to participate if: * they have a child younger than 2 months or 13 months old or older currently seeking outpatient care for a respiratory illness * the child is admitted to hospital * the child does not have a respiratory illness * the child has a diagnosed craniofacial syndrome * the child has a defined contraindication and cannot use a nasal aspirator * the parents/caregivers are not comfortable using a nasal aspirator * the parent/caregivers are not fluent in english

Keywords: nasal aspirator in infants user experience of nasal aspirators
effectiveness of technology-based interventions for the improvement of cognitive processes in adhd.

Conditions: ADHD, Deficits in Motor Control and Perception

Summary: to scientifically demonstrate the improvements in cognitive functions and core symptoms of children and adolescents diagnosed with adhd through the implementation of a cognitive rehabilitation program based on the use of the most relevant technologies found in the systematic review carried out during the first phase. two intervention groups will be randomly assigned for the study: g1: composed of 20 patients who will receive neurocognitive therapy based on new technologies. this will be the experimental group. g2: composed of 20 patients who will receive conventional neurocognitive therapy for adhd treatment. this group will be the control group


Eligibility criteria:
inclusion criteria: * children and adolescents diagnosed with adhd * age: 6-17 years old exclusion criteria: * children and adolescents diagnosed with adhd + add. * age: under 6 years old or over 17 years old. * other psychopharmacological treatments not specific for adhd.

Keywords: adhd cognitive rehabilitation new technologies
the role of vitamin k on knee osteoarthritis outcomes

Conditions: Osteo Arthritis Knee

Summary: the appropriate form and dosing of vitamin k to benefit relevant outcomes in knee osteoarthritis (oa) are not known. in intervention studies for conditions other than knee oa (e.g., prevention of cardiovascular disease), the most commonly used forms and doses include phylloquinone (vitamin k1; 1000µg or 500µg daily) or menaquinone-7 (mk-7 or vitamin k2; 300µg daily). however, whether these doses are adequate to increase vitamin k to levels that ameliorate risk of adverse oa outcomes is not known. furthermore, although some studies suggest enhanced bioavailability of mk-7 over vitamin k1, as well as extra-hepatic effects, whether this is relevant for an older population with knee oa is not known, the overall goal of this pilot randomized clinical trial (rct) is to test different subtypes and doses of vitamin k supplementation in older adults with knee oa and to measure changes in relevant biochemical measures.


Eligibility criteria:
inclusion criteria: * ≥60 years old * clinical diagnosis of knee oa by the treating rheumatologist * english fluency exclusion criteria: * anticoagulation use (including warfarin, dabigatran, rivaroxaban, apixaban)

Keywords: vitamin k-1 vitamin k-2 menaquinone-7 (mk-7) uncarboxylated matrix gla protein (ucmgp) phylloquinone
systemic mechanisms in allergic rhinitis: assessment of metabolomic outcomes.

Conditions: Allergic Rhinitis

Summary: this clinical study will use the environmental exposure unit (eeu) to generate allergic rhinitis symptoms in participants under controlled conditions, to collect well-characterized biological samples (urine and blood) before and after they develop these symptoms. the eeu provides the ability to control the timing, duration and levels of allergen exposure, and also other outside environmental factors, yielding ideal biologic samples for analysis with novel, cutting-edge molecular techniques. results from the analysis of these unique allergic rhinitis samples should help determine if the technique of urine nuclear magnetic resonance analysis could be a useful diagnostic tool in allergic rhinitis. ige testing will be done on blood samples and compared to spin prick testing and symptoms of allergic rhinitis.


Eligibility criteria:
inclusion criteria: * participant is a healthy, ambulatory male or female volunteer 18 to 55 years of age. * participant has a history of seasonal allergic rhinitis due to ragweed for the last two consecutive ragweed seasons. * participant has a positive response (wheal diameter greater than or equal to 3 mm larger than diluent control) to a skin prick test to short ragweed allergen at screening or within 12 months of screening visit. exclusion criteria: * participant is a female that is pregnant, lactating or actively trying to become pregnant. * smokers * participant is unable to comply with the washout periods for prohibited medications. * participant is currently receiving allergen specific immunotherapy injections.

Keywords: allergic rhinitis nmr
efficacy-safety study of sublingual immunotherapy with depigmented-polymerized pollen extracts to treat rhinoconjunctivitis

Conditions: Allergic Rhinoconjunctivitis

Summary: as the principal objective of this study is to evaluate the efficacy and safety of the treatment measuring the changes in a symptom score, the patient will be asked to fill in a patient diary. this diary will evaluate the week before the patient comes back to receive the treatment. nose (sneeze, blockage and running), eye (itching, redness and swelling) and chest (breathlessness, wheeze, chest tightness), are scored on a scale from the patient will be instructed to daily assess each one of the symptoms, recording them on an individual symptoms follow-up diary.

the study drug is a sublingual immunotherapy (vaccine) with allergenic extract of grass pollen (lolium perenne (50%) + cynodon dactylon (50%)). sublingual immunotherapy has been available on the european market to treat patients with allergic rhinoconjunctivitis (itching, sneezing, stuffy nose, runny nose) for many years. in this study it will be used as drops under the tongue. at the beginning of the study, you will be given a card that documents that you are taking part. please carry this with you at all times, in case treatment is necessary at another location. the drops will be given at two doses. the drops are held under the tongue for 2 minutes prior to swallowing.sublingual immunotherapy has been shown to be safe and effective in reducing the symptoms of allergic rhinoconjunctivitis (nasal allergy and allergy of the eyes).

Eligibility criteria:
inclusion criteria: * clinical history of allergic rhinoconjunctivitis and/or asthma due to hypersensitivity to grass mix lolium perenne and cynodon dactylon. * male or female subjects between 18 and 50 years old * positive skin tests to lolium perenne and cynodon dactylon: the wheal produced by the skin test by means of the prick-test technique must be equal or superior to the wheal produced by the positive control of prick test (histamine 10 mg/ml). * presence of specific ige to lolium perenne and cynodon dactylon (cap greater than 17.5k u/l). * female subjects must not be sexually active or must be following a medially accepted contraceptive method. * pregnancy test negative exclusion criteria: * treatment with ß-blocking agents * patients suffering from some pathology in which the adrenaline is contraindicated (hyperthyroidism, hta, cardiopathy, etc.) * autoimmune disease (thyroiditis, lupus, etc.) * conditions in which the patient can not offer full co-operation, compliance or those with significant psychiatric disturbance. * intolerance to aspirin. * pregnant women or with pregnancy risk and breast-feeding women

Keywords: allergic rhinoconjunctivitis, immunotherapy
regulation of intraarticular and synovium-related biomarkers of osteoarthritis. effect of acute mechanical joint loading

Conditions: Osteoarthritis; Exercise

Summary: in the present study the microdialysis method is used to investigate biochemical changes within and around the joint simultaneously in both the resting state and in a joint that had been subjected to exercise. the aim of the present study was, by applying the microdialysis technique, to monitor markers of cartilage breakdown and inflammation in 2 different positions of the knee (inside and in the inner part of the knee capsule) in a group of human females with knee osteoarthritis over a period of 3 hours.


Eligibility criteria:
inclusion criteria: * verified osteoarthritis (x-ray)of the knee, female, exclusion criteria: * dementia, inflammatory diseases, regular pain medication

Keywords: osteoarthritis biochemical markers cartilage inflammation microdialysis